akerotx (@akerotx) header
akerotx (@akerotx) profile picture

Advancing transformational new medicines that restore metabolic balance to treat serious metabolic diseases.

San Francisco, CA
Joined June 2018
Photo by akerotx (@akerotx)Photo by akerotx (@akerotx)Photo by akerotx (@akerotx)Photo by akerotx (@akerotx)Photo by akerotx (@akerotx)Photo by akerotx (@akerotx)Photo by akerotx (@akerotx)Photo by akerotx (@akerotx)Photo by akerotx (@akerotx)Photo by akerotx (@akerotx)
📌In our January issue A randomized, double-blind, placebo-controlled phase IIa trial of #efruxifermin for patients with compensated #NASHcirrhosis 🔓#OpenAccess at👉https://xitter.gq/t.co/7BegSiqWJs #LiverTwitter
8
7
2,064
Akero shares soar as #NASH drug succeeds in mid-stage trial biopharmadive.com/news/akero… $AKRO + 116% $ETNB + 33% $ICPT $MDGL
1
4
Shares of @akerotx surged more than 104% in premarket trading after the announcement that efruxifermin improved liver fibrosis and prevented disease worsening in patients with pre-cirrhotic nonalcoholic steatohepatitis. #AkeroTherapeutics #BioSpace hubs.li/Q01mbx5g0
1
1
$AKRO - Akero stock soars 71% as drug improves liver fibrosis, prevents disease worsening in trial seekingalpha.com/news/388223…
1
2
🟪NEW Article in press❕ A randomized, double-blind, placebo-controlled phase IIa trial of efruxifermin for patients with compensated NASH #cirrhosis 🔓#OpenAccess at👉https://xitter.gq/t.co/7BegSi9lkS #nonalcoholicsteatohepatitis #NALFD #LiverTwitter
5
1
10
JANUARY ISSUE | CONSENSUS STATEMENT Advancing the global public health agenda for #NAFLD: a consensus statement FREE nature.com/articles/s41575-0… #MAFLD #NASH #fattyliver #NoNASH
4
7
Our OCTOBER issue features this Expert Recommendation on defining comprehensive models of care for #NAFLD, the authors make 8 recommendations for the development of MOCs for NAFLD & #NASH go.nature.com/3jxl94S
3
9
#Thankyou for making International #NASHDay 2021 a resounding success. 🎉 Together, we continue to raise #awareness about #NASH & the actions that people can take to address this life-threatening disease. 🗓️Mark your Calendars: see you on June 9, 2022!
6
2
10
NASH is the advanced version of #fattyliverdisease caused by fat build-up in the liver. What's your risk? #NASHawareness #LiverDisease #LiverExperts
1
3
Efruxifermin an effective and safe treatment for nonalcoholic steatohepatitis dlvr.it/S3dDBK #ChronicDisease #Gastroenterology
2
2
Will long-acting FGF21 analogs prove safe and sufficiently effective for #NASH @NatureMedicine nature.com/articles/s41591-0…
4
1
24
Hear @AASLDtweets member speakers Stephen Harrison, MD, FACP, FAASLD, Col (ret.) USA and Kenneth Cusi, MD, FACP, FACE speak on #NASH and #Diabetes during #NASHday https://xitter.gq/t.co/bGlhpVazul
June 10th is International #NASHDay. Join advocates & partners from across the🌐as we spread awareness about this serious #liverdisease that is on the rise. Together we can make our voices heard! Join the conversation🙌#NASHDay⮕https://xitter.gq/t.co/yxJboTAUGK #NAFLD #NASH @GlobalLiver
“There has been a world of new data that has come forward relative to #diabetes & #fattyliverdisease in the past 12 months,” said Stephen A. Harrison, MD, FACP, FAASLD #NASHDay
IT'S INTERNATIONAL #NASHDAY! We love raising awareness & fighting for our patients! Thanks to #AKERO for the beautiful props! #PinnacleProud #RaiseAwareness #InternationalNASHDay
1
1
2
8